Comparison of In-House Methods & Cobas BRAF V600 Mutation Assay in

Clinical Trial Summary

This non-interventional study will compare the Cobas BRAF V600 mutation assay with in-house methods used in molecular laboratories for the assessment of the BRAF mutation status in melanoma tumor samples. No patients will be enrolled in this study. Data will be collected for approximately 6 months.

See also
Status	Clinical Trial	Phase
Completed	`NCT04229277` - Fast Track Diagnosis of Skin Cancer by Advanced Imaging	N/A
Completed	`NCT03653819` - High Intensity Interval Training (HIIT) for Patients With Cancer-related Lymphedema in the Lower Limbs	N/A
Active, not recruiting	`NCT04074096` - Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis	Phase 2
Completed	`NCT02935790` - Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab	Phase 1
Recruiting	`NCT05478876` - Carbon Ion Radiation Therapy in the Treatment of Mucous Melanomas of the Female Lower Genital Tract	N/A
Completed	`NCT01211262` - Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma	Phase 1
Recruiting	`NCT03649529` - Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy	Early Phase 1
Completed	`NCT03278665` - 4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy	Phase 1/Phase 2
Completed	`NCT04452214` - A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors	Phase 1
Terminated	`NCT02709889` - Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors	Phase 1/Phase 2
Completed	`NCT01455259` - Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors	Phase 1/Phase 2
Completed	`NCT00978913` - Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma	Phase 1
Completed	`NCT00232726` - Clinical Study of Previously Untreated Patients With Malignant Melanoma	Phase 2
Completed	`NCT00350597` - GM-CSF as Adjuvant Therapy of Melanoma	Phase 2
Completed	`NCT00336986` - Efficacy Study of IL-21 to Treat Metastatic Melanoma	Phase 2
Completed	`NCT02523313` - Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED	Phase 2
Completed	`NCT03545334` - Lymph Node Identification in Skin Malignancy Using ICG Transcutaneously Study	N/A
Completed	`NCT04253574` - Comparison of PET/CT and Ultrasound in Staging of Malignant Melanoma
Completed	`NCT00179608` - Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy	Phase 1
Terminated	`NCT00104884` - FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma	Phase 2

NCT number	NCT01744860
Study type	Observational
Source	Hoffmann-La Roche
Contact
Status	Completed
Phase	N/A
Start date	December 2012
Completion date	April 2013

Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms